Sunday, 16 August 2026European Markets
ExploreSearch
ViaNews EU
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 24, 2026

BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs

View original at globenewswire.com
BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfoli…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BioNTech currently has 16 clinical trials running for various lung cancer subtypes and treatment lines, including four registrational Phase 3 trials and five trials with innovative combination approaches

    60% confidence

  • Pumitamig data support the currently ongoing registrational Phase 3 trial ROSETTA Lung-01 for first-line treatment of extensive-stage small cell lung cancer

    60% confidence

  • The data presented at ELCC 2026 demonstrate the potential of BioNTech's late-stage lung cancer portfolio, with updates on Pumitamig and Gotistobart as well as first clinical data for HER3-targeted ADC candidate BNT326/YL202, driving forward differentiated treatment approaches for various lung cancer stages

    60% confidence

  • Gotistobart showed a clinically relevant overall survival benefit with a 54% reduction in mortality risk compared to current standard of care in second-line and later treatment of squamous lung cancer

    60% confidence

  • BioNTech's goal is to offer patients with lung cancer innovative treatment options that aim to enable significant long-term benefit across all disease stages

    60% confidence

Data points we hold from this source

BioNTech SE · combination therapy trials5 trials
BioNTech SE · active lung cancer trials16 trials
BioNTech SE · phase 3 trials4 trials
BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs — Source | Via News | ViaNews EU